TYK Medicines (HKSE:02410) Research & Development: HK$268.59 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02410 TYK Medicines Inc HKSE:02410
7 GF Score
Price HK$6.81
! 3 Warning Signs
View Full Analysis

What is TYK Medicines Research & Development?

TYK Medicines HKSE:02410 -4.08% 7 Research & Development is HK$268.59 Mil as of Dec. 2025. GuruFocus rates HKSE:02410 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. TYK Medicines's Research & Development for the six months ended in Dec. 2025 was HK$171.57 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$268.59 Mil.

TYK Medicines  (HKSE:02410) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TYK Medicines Research & Development Related Terms

TYK Medicines Research & Development Historical Data

* Premium members only.

The historical data trend for TYK Medicines's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TYK Medicines Research & Development Chart

TYK Medicines Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
256.63 272.63 251.38 269.62

TYK Medicines Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 141.99 148.30 104.30 97.02 171.57
HKSE:02410
7GF Score
TYK Medicines Inc HKSE:02410
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TYK Medicines Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$268.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$268.59 Mil mean?
TYK Medicines (HKSE:02410) has a Research & Development of HK$268.59 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on TYK Medicines and its competitors.
Is TYK Medicines' Research & Development too high?
TYK Medicines' current Research & Development is HK$268.59 Mil. Overall, TYK Medicines has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' Research & Development compare to VRTX and REGN?
TYK Medicines' Research & Development of HK$268.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TYK Medicines and its competitors. TYK Medicines's current Research & Development is HK$268.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current Research & Development of HK$268.59 Mil. The current Research & Development is HK$268.59 Mil. TYK Medicines' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current Research & Development is HK$268.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TYK Medicines Business Description

Address No.277 Longlan Road, 8th Floor, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai, CHN
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
7GF Score

Get the complete analysis for HKSE:02410

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.81
Price